A senior official the National Institutes of Health has told agency staff not to cancel any more research projects for the time being in the wake of two court rulings taking umbrage with the cancellation of medical research grants by the Trump administration, the New York Times’ Benjamin Mueller reports, citing an internal memo. The directive marks a retreat by the agency, as it has slashed funding for medical research since Trump’s return to office by terminating hundreds of awards, the author notes. Shares of Illumina (ILMN), Thermo Fisher (TMO), Avantor (AVTR), and Bruker (BRKR) moved higher following the news, while Icon (ICLR) and Medpace (MEDP) were still in the red but curtailed some earlier losses.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Cathie Wood’s ARK Investment buys 28K shares of Illumina today
- Illumina’s Strategic Acquisition of SomaLogic: Hold Rating Reaffirmed Amidst Unchanged Financial Outlook
- Cautious Hold Rating on Illumina Amid Uncertain Financial Impact of SomaLogic Acquisition
- Illumina price target raised to $85 from $77 at Barclays
- Illumina’s Strategic Acquisition of SomaLogic Faces Near-Term Challenges and Market Uncertainties